Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

P. Joly; B. Horvath; Patsatsi; S. Uzun; R. Bech; S. Beissert; R. Bergman; P. Bernard; L. Borradori; M. Caproni; F. Caux; G. Cianchini; M. Daneshpazhooh; D. De; M. Dmochowski; K. Drenovska; J. Ehrchen; C. Feliciani; M. Goebeler; R. Groves; C. Guenther; S. Hofmann; D. Ioannides; C. Kowalewski; R. Ludwig; Y. L. Lim; B. Marinovic; A. V. Marzano; J. M. Mascaró; D. Mimouni; D. F. Murrell; C. Pincelli; C. P. Squarcioni; M. Sárdy; J. Setterfield; E. Sprecher; S. Vassileva; K. Wozniak; S. Yayli; G. Zambruno; D. Zillikens; M. Hertl; E. Schmidt

doi:10.1111/jdv.16752

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

P. Joly^*, B. Horvath, Patsatsi, S. Uzun, R. Bech, S. Beissert, R. Bergman, P. Bernard, L. Borradori, M. Caproni, F. Caux, G. Cianchini, M. Daneshpazhooh, D. De, M. Dmochowski, K. Drenovska, J. Ehrchen, C. Feliciani, M. Goebeler, R. GrovesC. Guenther, S. Hofmann, D. Ioannides, C. Kowalewski, R. Ludwig, Y. L. Lim, B. Marinovic, A. V. Marzano, J. M. Mascaró, D. Mimouni, D. F. Murrell, C. Pincelli, C. P. Squarcioni, M. Sárdy, J. Setterfield, E. Sprecher, S. Vassileva, K. Wozniak, S. Yayli, G. Zambruno, D. Zillikens, M. Hertl, E. Schmidt

^*Corresponding author for this work

Abstract

Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	34
Issue number	9
Pages (from-to)	1900-1913
Number of pages	14
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.16752
Publication status	Published - 01.09.2020

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdv.16752

Cite this

Joly, P., Horvath, B., Patsatsi, Uzun, S., Bech, R., Beissert, S., Bergman, R., Bernard, P., Borradori, L., Caproni, M., Caux, F., Cianchini, G., Daneshpazhooh, M., De, D., Dmochowski, M., Drenovska, K., Ehrchen, J., Feliciani, C., Goebeler, M., ... Schmidt, E. (2020). Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 34(9), 1900-1913. https://doi.org/10.1111/jdv.16752

@article{eb6a823139844308bc4671cedfef1583,

title = "Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)",

abstract = "Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.",

author = "P. Joly and B. Horvath and Patsatsi and S. Uzun and R. Bech and S. Beissert and R. Bergman and P. Bernard and L. Borradori and M. Caproni and F. Caux and G. Cianchini and M. Daneshpazhooh and D. De and M. Dmochowski and K. Drenovska and J. Ehrchen and C. Feliciani and M. Goebeler and R. Groves and C. Guenther and S. Hofmann and D. Ioannides and C. Kowalewski and R. Ludwig and Lim, {Y. L.} and B. Marinovic and Marzano, {A. V.} and Mascar{\'o}, {J. M.} and D. Mimouni and Murrell, {D. F.} and C. Pincelli and Squarcioni, {C. P.} and M. S{\'a}rdy and J. Setterfield and E. Sprecher and S. Vassileva and K. Wozniak and S. Yayli and G. Zambruno and D. Zillikens and M. Hertl and E. Schmidt",

note = "{\textcopyright} 2020 European Academy of Dermatology and Venereology.",

year = "2020",

month = sep,

day = "1",

doi = "10.1111/jdv.16752",

language = "English",

volume = "34",

pages = "1900--1913",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

number = "9",

}

Joly, P, Horvath, B, Patsatsi, Uzun, S, Bech, R, Beissert, S, Bergman, R, Bernard, P, Borradori, L, Caproni, M, Caux, F, Cianchini, G, Daneshpazhooh, M, De, D, Dmochowski, M, Drenovska, K, Ehrchen, J, Feliciani, C, Goebeler, M, Groves, R, Guenther, C, Hofmann, S, Ioannides, D, Kowalewski, C, Ludwig, R, Lim, YL, Marinovic, B, Marzano, AV, Mascaró, JM, Mimouni, D, Murrell, DF, Pincelli, C, Squarcioni, CP, Sárdy, M, Setterfield, J, Sprecher, E, Vassileva, S, Wozniak, K, Yayli, S, Zambruno, G, Zillikens, D, Hertl, M & Schmidt, E 2020, 'Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)', Journal of the European Academy of Dermatology and Venereology, vol. 34, no. 9, pp. 1900-1913. https://doi.org/10.1111/jdv.16752

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). / Joly, P.; Horvath, B.; Patsatsi et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 34, No. 9, 01.09.2020, p. 1900-1913.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

AU - Joly, P.

AU - Horvath, B.

AU - Patsatsi,

AU - Uzun, S.

AU - Bech, R.

AU - Beissert, S.

AU - Bergman, R.

AU - Bernard, P.

AU - Borradori, L.

AU - Caproni, M.

AU - Caux, F.

AU - Cianchini, G.

AU - Daneshpazhooh, M.

AU - De, D.

AU - Dmochowski, M.

AU - Drenovska, K.

AU - Ehrchen, J.

AU - Feliciani, C.

AU - Goebeler, M.

AU - Groves, R.

AU - Guenther, C.

AU - Hofmann, S.

AU - Ioannides, D.

AU - Kowalewski, C.

AU - Ludwig, R.

AU - Lim, Y. L.

AU - Marinovic, B.

AU - Marzano, A. V.

AU - Mascaró, J. M.

AU - Mimouni, D.

AU - Murrell, D. F.

AU - Pincelli, C.

AU - Squarcioni, C. P.

AU - Sárdy, M.

AU - Setterfield, J.

AU - Sprecher, E.

AU - Vassileva, S.

AU - Wozniak, K.

AU - Yayli, S.

AU - Zambruno, G.

AU - Zillikens, D.

AU - Hertl, M.

AU - Schmidt, E.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.

AB - Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.

UR - http://www.scopus.com/inward/record.url?scp=85089747894&partnerID=8YFLogxK

U2 - 10.1111/jdv.16752

DO - 10.1111/jdv.16752

M3 - Journal articles

C2 - 32830877

AN - SCOPUS:85089747894

SN - 0926-9959

VL - 34

SP - 1900

EP - 1913

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 9

ER -

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this